SBT-272 improved neuronal health, superior to other approved and investigational agents Phase 1 study to evaluate safety and tolerability of SBT-272 in healthy volunteers is underway Get our FREE Newsletter! Discover Stocks with +1,000% Upside … Continue reading Stealth BioTherapeutics (NASDAQ: MITO) Presents New SBT-272 Data Demonstrating Improvement in Upper Motor Neuron Function in ALS Disease Model at Keystone Neurodegeneration Symposium